The effect of recent drug approvals on translational research and drug development.
Atkins
Michael B
MB
Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, and Harvard Medical School, Boston, MA 02215, USA.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use*; D035843:Biomedical Research; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D017277:Drug Approval; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D020935:MAP Kinase Signaling System / Q000187:drug effects; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D000077157:Sorafenib; D000077210:Sunitinib; D014481:United States; D014486:United States Food and Drug Administration
D020533:Angiogenesis Inhibitors; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D011505:Protein-Tyrosine Kinases; D017346:Protein Serine-Threonine Kinases; D000077210:Sunitinib